Amgen Inc. reported that third-quarter 2020 adjusted profit rose 17% due to stronger sales of drugs such as the osteoporosis treatment Prolia and the psoriasis medication Otezla, bucking challenges from lower drug prices and Covid-19.
Sanofi forecast a return to profit growth in 2018, but the company’s shares fell as analysts had hoped for a bigger boost from recent deals and a revamped drugs pipeline.
Eli Lilly and Company today announced its 2018 financial guidance, including low-single-digit revenue growth driven by volume from recently launched pharmaceutical products. The company also highlighted key events for 2018, including continued progress on Lilly’s pipeline.
Mylan NV raised the lower end of its 2017 forecasts as the U.S. drugmaker expects to benefit from the earlier-than-expected approval of its copycat of Teva’s blockbuster multiple sclerosis treatment Copaxone.
Teva Pharmaceutical Industries said it would miss 2017 profit forecasts due to competition in the U.S. market and weakening sales of the company’s multiple sclerosis drug Copaxone, hammering shares for the world’s largest generic medicine maker.
Philips expects sales to grow by 4-to-6 percent in the coming three years as the Dutch company focuses on growth in the health technology market.
Endo International Plc forecast earnings for the third quarter well above analysts’ estimates amid a lawsuit filed by it against U.S. health regulators that seeks to protect the drugmaker’s blood pressure drug franchise.
Johnson & Johnson indicated in its third-quarter 2017 financial announcement that the company is dropping two of its pipeline drugs.